Introduction
============

Zolpidem is a gamma-aminobutyric acid (GABA) agonist that is indicated for the treatment of insomnia characterized by difficulties with sleep initiation. Sex-specific differences in pharmacokinetics (PK) have been observed in which females have greater exposure than males and have increased probabilities of experiencing undesired, persistent pharmacological effect after waking (typically drowsiness) ([@B22], [@B20]; [@B38]). To address sex-related adverse events, the FDA reduced the recommended initial dose by half in females ([@B13]).

Zolpidem is hydroxylated by CYP3A4, rapidly oxidized to an aldehyde by alcohol dehydrogenases (ADHs), and finally converted into a carboxylic acid by aldehyde dehydrogenases (ALDHs). The major circulating metabolite is zolpidem phenyl 4-carboxylic acid (ZPCA; 72--86%), with zolpidem 6-carboxylic acid (ZCA) making up roughly ∼10% of the administered dose ([@B18]; [@B32]). It is currently unknown which ADH/ALDH enzyme classes are responsible for the metabolism of zolpidem, and whether gastric ADH/ALDH pathways contribute to zolpidem disposition. Nevertheless, along with certain cytochromes P450, such as CYP3A that acts synergistically with other enzymes in the gastric mucosa of humans and animals ([@B44]), the ADH/ALDH enzyme pathway is likely the major contributor to the bioavailability and elimination of zolpidem.

CYP3A4 activity is greater in females and is therefore unlikely to result in slower metabolism in women ([@B42]). However, it is well known that ADH/ALDH expression in the gastrointestinal (GI) tract is much lower in females vs. males, likely due to differences in androgens (**Table [1](#T1){ref-type="table"}**). Low ADH activity would be expected to slow CYP3A4 zolpidem metabolism due to inefficient removal of the products of CYP3A4-mediated zolpidem metabolism, based on Le Chatelier's principle. Sex hormone concentration differences are also responsible for variability in ADH expression in aging, which is consistent with the observed reduction in zolpidem clearance in older individuals ([@B21]). Similar sexual- and age-dimorphic Adh expression profiles have also been observed in the GI tracts and livers of rats ([@B12]; [@B1]; [@B41]).

###### 

Alcohol dehydrogenase (Adh) Class 1-V and Aldh isozymes in humans and rats.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme class                                Isozymes in humans                                             Human expression sites                       Rat expression sites                                                                                               Sexually dimorphic expression M vs. F          Metabolic parameter                                   Reference
  ------------------------------------------- -------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- ----------------------------------------------------- -------------------------------
  **ADH**                                                                                                                                                                                                                                                                                                                   **Ethanol Km (mM), Vmax (min^-1^)**                   

  Class I                                     *ADH1A ADH1B^∗^1, ADHB^∗^2, ADH1B^∗^3, ADH1C^∗^1, ADH1C^∗^2*   Liver (all) and stomach (ADH1C^∗^1)          Duodenum, colon, rectum, liver, kidney, stomach, greatest expression in the above tissues vs. other ADH classes.   Higher in female rats' liver\                  4.0, 30\                                              [@B12]; [@B1]; [@B41]
                                                                                                                                                                                                                                                                             Lower in female rats' gastrointestinal tract   0.05, 4\                                              
                                                                                                                                                                                                                                                                                                                            0.9, 350\                                             
                                                                                                                                                                                                                                                                                                                            40.0, 300\                                            
                                                                                                                                                                                                                                                                                                                            1.0, 90\                                              
                                                                                                                                                                                                                                                                                                                            0.6, 40                                               

  ADH2                                        *ADH4*                                                         Liver                                        Liver, kidney, stomach, duodenum                                                                                   Lower in female rats' liver                    30, 20                                                [@B12]; [@B1]

  ADH3                                        *ADH5*                                                         Most tissues                                 Tongue, esophagus, stomach, duodenum, jejunum, Ileum, colon, rectum, liver, kidney, stomach                        None                                           \>1000, 100                                           [@B12]; [@B41]

  ADH4                                        *ADH7*                                                         Gastric mucosa                               Tongue, esophagus, stomach                                                                                         ?                                              30, 1800                                              [@B41]

  ADH5                                        ADH6                                                                                                        Liver, stomach                                                                                                     ?                                              ?. ?                                                  

  **ALDH (9 classes, but 3 major in rats)**                                                                                                                                                                                                                                                                                 **Disulfiram IC50 of acetaldehyde metabolism (uM)**   [@B34]

  ALDH1 (RalDH)                               None                                                           Cytosolic (high *K*~m~ for acetaldehyde)     Tongue, esophagus, stomach, duodenum, jejunum, not detectible in liver                                             ?                                              Human 0.15\                                           [@B25]; [@B5]; [@B41]; [@B26]
                                                                                                                                                                                                                                                                                                                            Rat0.10                                               

  ALDH2                                       None                                                           Mitochondria (Low *K*~m~ for acetaldehyde)   Liver                                                                                                              ?                                              Human 1.45\                                           [@B25]; [@B26]
                                                                                                                                                                                                                                                                                                                            Rat \>20                                              

  ALDH3                                       Constitutive, xenobiotic inducible                                                                          GI tract                                                                                                           ?                                              ?                                                     [@B27]; [@B43]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADH expression is greatest in the liver while smaller amounts have been observed in the GI tract and the kidney ([@B12]; [@B1]; [@B41]). The ALDH inhibitor, disulfiram, slows ADH metabolism by irreversibly inhibiting the elimination of aldehydes formed by ALDH (IC~50~ = 0.15 uM for ALDH1; IC~50~ = 1.45 uM for ALDH2) ([@B26]) and therefore shifts the alcohol-aldehyde equilibrium toward hydroxides ([@B3]; [@B4]). Without ADH/ALDH to further metabolize hydroxyl metabolites, a buildup of these could be compensated by reduced production by CYPs, possibly due to mechanism-based inhibition ([@B33]). However, a potential zolpidem/disulfiram interaction has not been studied. We therefore hypothesized that sexual dimorphism in the expression of ADH and ALDH in males and females is responsible for the observed sex differences in zolpidem exposure, and that disulfiram treatment would therefore have similar effects as castration via bypass of gastric ADH/ALDH metabolism. The preclinical pilot study described here details the PK analysis of zolpidem in Sprague--Dawley rats in order to provide a preliminary understanding of the observed clinical differences in zolpidem PK and pharmacodynamics (PD) between males and females.

Materials and Methods {#s1}
=====================

Materials
---------

Zolpidem free base (≥98% purity by HPLC) was purchased from Sigma--Aldrich (St. Louis, MO, USA) through the NIH Pharmacy. Zolpidem phenyl 4-carboxylic acid (ZPCA), ZCA, and \[H^2^\]~6~-zolpidem (D6-zolpidem) were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Stock solutions were prepared in DMSO (Sigma--Aldrich) that was subsequently diluted in a 1% sucrose (aq) solution for oral gavage. Male and female Sprague--Dawley rats were obtained from Charles River Labs (Germantown, MD, USA). Disulfiram was purchased from Sigma--Aldrich (St. Louis, MO, USA) as European Pharmacopeia grade reference standard and was formulated for intraperitoneal injection in a 1% suspension of carboxy methylcellulose (CMC), purchased from Sigma--Aldrich (St. Louis, MO, USA), as previously described ([@B35]).

Study Design
------------

Rats were separated into 5 treatment groups, each receiving 2.6 mg/kg zolpidem: (1) Group 1: uncastrated males receiving CMC vehicle control (MC); (2) Group 2: uncastrated males receiving disulfiram (MD); (3) Group 3: females receiving disulfiram (FD); (4) Group 4: females receiving CMC vehicle control (FC); and (5) Group 5: castrated males receiving CMC vehicle control (cMC). Disulfiram was administered intraperitoneally at a dose of 100 mg/kg approximately 16 h before the middle of each zolpidem time point in order to ensure Aldh inhibition was maximal ([@B17]). For example, rats corresponding to the 8 h time point were administered disulfiram 12 h prior to zolpidem administration (mid-point of the 8-h time is 4 h, thus 12 h prior to dose is 16 h) whereas rats corresponding to the 1 h time point were treated 15.5 h prior to zolpidem administration. All rats were given food and water ad libidum. Zolpidem was administered as an oral gavage (volume 2 mL) at a dose of 2.6 mg/kg as had been used previously ([@B16]). Male rats in Group 5 (cMC) were castrated according to an NIH Animal Care and Use Committee (ACUC) approved procedure ([@B11]). Briefly, castration surgeries were preformed through the abdominal wall. To initiate and maintain the plane of anesthesia, 2.5% vaporized isoflurane was inhaled with a 1.5 L/min flow rate. Excision of the entire testicle and epididymis was accomplished by suturing spermatic vessels and vas deferens closed. The peritoneum was closed with 4--0 absorbable sutures and the outer abdominal skin with surgical clips. Marcaine drops were used as a nerve block and buprenorphine as an analgesic. During recovery, animals were kept warm and watched until able to walk. They were then returned to their cages and per protocol, were checked every day after surgery for 5 days. After 10 days, surgical clips were removed. All castrated males were treated with zolpidem 14 days after castration since serum testosterone concentrations approach levels observed in females after that time, and a previous work demonstrated Adh/Aldh differences in rats that were only castrated for 7 days ([@B1]; [@B6]). All animal care and maintenance was in accordance with NIH ACUC guidelines.

PK Sampling and Sample Bioanalysis
----------------------------------

To examine the PK profile of zolpidem following oral gavage, blood samples were collected in heparinized tubes via cardiac puncture, and immediately placed on ice. Carbon dioxide asphyxiation was conducted to ensure euthanasia and brains were then harvested from each rat. Samples (plasma and whole brain) were obtained at 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, and 8 h post gavage. Each time point was performed in three rats within each group (seven time points in triplicate = 21 rats per group). Immediately after collection, blood samples were centrifuged for 5 min at 1200 ×*g*. The plasma supernatant was then immediately transferred to a cryovial and stored at -80°C until the time of bioanalysis. Brains were snap-frozen and stored until needed, when they were thawed and homogenized for bioanalysis. Plasma and brain concentrations of zolpidem and its two major carboxylic acid metabolites ZPCA and ZCA were quantitatively measured using a validated HPLC with tandem mass spectrometric detection (HPLC-MS/MS) method with a calibration range of 0.5--1,000 ug/L (ng/mL). Briefly, 100 uL of rat plasma was spiked with ^2^\[H\]~6~-zolpidem (internal standard), acetonitrile was then added to precipitate proteins. The acetonitrile extract was dried and the residue reconstituted. Zolpidem, ZPCA, and ZCA had chromatographic retention times of 4.8min, 3.6min, and 4.1 min, respectively; the deuterated internal standard (^2^\[H\]~6~-zolpidem) eluted at the same time as unlabeled zolpidem The assay was validated per FDA guidelines, with accuracy and precision of calibration standards and quality control standards less than 15% ([@B14]).

Non-compartmental Analysis
--------------------------

A naïve-pooled, sparse non-compartmental (model-independent) approach was used to calculate plasma and brain PK parameters of zolpidem and the two metabolites, treating all data as originating in one "average" rat, using Phoenix WinNonlin v6.4 (Certara Pharsight Corporation, Cary, NC, USA). Any plasma or brain concentration measured below the LLOQ (0.5 ug/L) was excluded from analyses. The maximum plasma concentration (*C*~MAX~) and time to *C*~MAX~ (*T*~MAX~) were recorded as the mean (*n* = 3 per group) of observed values; the area under the plasma concentration vs. time curve (AUC~LAST~) was calculated using the linear trapezoidal rule as a linear combination of the mean concentration values using observable times up to 8 h. The standard error (SE) of the average *C*~MAX~ value in each treatment group was calculated as the sample standard error of the concentration values at the observed *T*~MAX~. The SE of the mean AUC~LAST~ estimate from destructive sampling was calculated according to the method of [@B29]. Bailer's method *Z*-tests were used to calculate the statistical differences in AUC between groups of rats using Microsoft Excel^®^ ([@B2]). Graphs were prepared using GraphPad Prism, v6.01 (GraphPad Software, San Diego, CA, USA) as well as all statistical analyses (except Bailer's), where a two-sided *p* \< 0.05 was considered to be statistically significant.

Statistical Considerations
--------------------------

Comparisons between PK parameters (except AUC, which was calculated with Bailer's analysis) were conducted with the Student's *t*-test. Several comparisons were conducted with only *n* = 3 rats in each group; therefore, individual PK parameters have low power to detect differences between rats and comparisons of such data will be reported as the mean and 95% CI.

Results
=======

Comparison of Zolpidem PK by Sex and Castration Status
------------------------------------------------------

The concentration-time profiles for zolpidem, ZPCA and ZCA from each treatment group are depicted in **Figure [1](#F1){ref-type="fig"}**. There was relatively low response variability at most time points, however, eight individual data points (i.e., individual samples from eight rats) were excluded from analyses either due to noted errors in gavage or blood draw technique (7/8), or the resulting plasma concentration from bioanalysis being approximately 10 SDs above the mean (1/8). The PK of zolpidem in males and females treated with vehicle (1% CMC) were compared to demonstrate the existence of sexual dimorphism in zolpidem clearance our animal model. Consistent with human studies ([@B22], [@B20]), female rats had a 1.7-fold higher *C*~MAX~ than males (112 \[36.4--188\] vs. 68.1 \[0.94--135\] ug/L; **Figure [2A](#F2){ref-type="fig"}**) and a 2.3-fold higher zolpidem AUC~LAST~ (538 \[419--657\] vs. 232 \[172-291\] h^∗^ug/L; **Figure [2B](#F2){ref-type="fig"}**). We therefore proposed that the gonadal testosterone secretion was, in part, responsible for this sex effect, and that this PK sex difference was likely related to differences in Adh/Aldh expression rather than Cyp3a.

![**Zolpidem plasma concentration vs. time profiles in **(A)** Group 1: uncastrated males + vehicle (1% CMC, i.p.), **(B)** Group 2: uncastrated males + disulfiram (suspended in 1% CMC, i.p.), **(C)** Group 5: castrated males + vehicle, **(D)** Group 4: females + vehicle, and **(E)** Group 3: females + disulfiram.** Zolpidem (open squares), the major metabolite zolpidem phenyl 4-carboxylic acid (red circles), and the minor metabolite zolpidem 6-carboxylic acid (ZCA) (blue triangles) were measured in rat plasma at varying time points post oral gavage of 2.6 mg/kg either with the ADH/ALDH inhibitor disulfiram, or its vehicle (CMC).](fphar-07-00260-g001){#F1}

![**Zolpidem plasma **(A)***C*~max~ and **(B)** AUC~last~ by sex and castration status, and **(C)***C*~max~ and **(D)** AUC~last~ by sex and disulfiram status.** Data are represented by bar graphs depicting the mean ± the standard error of the mean (SEM), and *p*-values were determined by Bailer's *Z*-test.](fphar-07-00260-g002){#F2}

To test this latter hypothesis, zolpidem PK from castrated male rats were compared to uncastrated male rats. Castrated males had 1.5-fold higher zolpidem AUC~LAST~ (340 \[215--464\] h^∗^ug/L) and 1.6-fold higher *C*~MAX~ (109 \[21.1--197\] ug/L) that was remarkably similar to females (**Figures [2A,B](#F2){ref-type="fig"}**) and occurred at a much earlier time point (*T*~MAX~ = 15 min) than uncastrated males and females (*T*~MAX~ = 60 min). Plasma exposure was also greater at 15 and 30 min (AUC~0-15\ min~ or AUC~0-30\ min~, fold change ≥1.9), further suggesting that castrated male rats were exposed to greater levels of zolpidem earlier than uncastrated males or females. Castration also induced a longer half-life (5.9 h vs. 3.3 h) compared to uncastrated males. Nevertheless, castration appeared to affect first pass metabolism more than other PK parameters, and the early rise in plasma concentration (i.e., AUC~0-30\ min~ and *C*~MAX~) was solely responsible for the greater overall AUC~LAST~ observed in castrated males vs. uncastrated males.

Comparison of Zolpidem PK with or without Disulfiram
----------------------------------------------------

We next determined the effect of Adh/Aldh inhibition on zolpidem metabolism by disulfiram, a potent ALDH inhibitor. Disulfiram pretreatment resulted in very rapid absorption of zolpidem (*T*~MAX~ = 5min) with a *C*~MAX~ that was 1.9-fold higher in males (128 \[86.6--168\] ug/L), and only slightly higher in females (145 \[-1.29--291\] ug/L; **Figure [2C](#F2){ref-type="fig"}**). This result was not unexpected as male rats have been shown to express more gastric Adh, which would be susceptible to greater inhibition than females (see **Table [1](#T1){ref-type="table"}**). Within each sex receiving disulfiram, zolpidem AUC unexpectedly decreased (**Figure [2D](#F2){ref-type="fig"}**). This observation suggests that the effect of disulfiram on zolpidem metabolism may be dependent on the differential expression of the Adh/Aldh isoenzyme along the GI tract.

Comparison of Zolpidem Plasma and Brain Pharmacokinetics
--------------------------------------------------------

Brain concentrations of zolpidem strikingly paralleled the plasma profile over time, consistent with a previous report (**Figure [3](#F3){ref-type="fig"}**) ([@B16]). Consequently, active drug penetrates into the brain earlier (i.e., faster *T*~MAX~; 5 min vs. 1 h in males; 15 min vs. 30 min in females), and is more rapidly removed from the brain in the presence of disulfiram causing lower zolpidem brain AUC~LAST~ in females (185 \[145--225\] vs. 286 \[211--361\] h^∗^ng/g) and males (107 \[70.3--143\] vs. 165 \[86.2--244\] h^∗^ng/g; **Figure [4](#F4){ref-type="fig"}**). Females also had higher brain AUC (286.1 \[211--361\] vs. 165 \[86.2--244\] h^∗^ng/g) and *C*~MAX~ (104 \[-40.7--249\] vs. 64.5 \[-38.5--167\] ng/g; **Figure [4](#F4){ref-type="fig"}**) than males. However, brain zolpidem PK in castrated and uncastrated males were similar for *C*~MAX~ and AUC. Brain tissue exposure to ZPCA was limited, and no brain samples had measureable ZCA concentrations.

![**Zolpidem plasma and brain concentration vs. time profiles in **(A)** Group 1: uncastrated males + vehicle (1% CMC, i.p.), **(B)** Group 2: uncastrated males + disulfiram (suspended in 1% CMC, i.p.), **(C)** Group 5: castrated males + vehicle, **(D)** Group 4: females + vehicle, and **(E)** Group 3: females + disulfiram.** Plasma concentrations (open squares) and brain concentrations (red squares) of zolpidem were measured in rats at varying time points post oral gavage of 2.6 mg/kg either with the ADH/ALDH inhibitor disulfiram, or its vehicle (CMC).](fphar-07-00260-g003){#F3}

![**Zolpidem brain **(A)***C*~max~ and **(B)** AUC~last~ by sex and castration status, and **(C)***C*~max~ and **(D)** AUC~last~ by sex and disulfiram status.** Data are represented by bar graphs depicting the mean ± the standard error of the mean (SEM), and *p*-values were determined by Bailer's *Z*-test.](fphar-07-00260-g004){#F4}

Discussion
==========

A sparse non-compartmental analysis demonstrated that a 2.6 mg/kg dose of zolpidem provided a *C*~MAX~ (68.1 ug/L), *T*~MAX~ (1 h) and half-life (3.3 h) in uncastrated male rats (MC) that were within reported ranges for healthy human adults given a 5 mg oral dose (**Table [2](#T2){ref-type="table"}**) ([@B13]; [@B23]). Human adult *C*~MAX~, *T*~MAX~, and half-life ranged between 30 and 113 ug/L, 0.79--1.61 h, and 1.4--4.5 h, respectively, ([@B13]; [@B23]; [@B36]). Zolpidem AUC~LAST~ values in MC rats (Mean \[95%CI\]: 232 \[172--291\] h^∗^ug/L) matched well with a previous report in healthy human adults (234 h^∗^ug/L) ([@B40]), but rats demonstrated a faster apparent CL/F (9 L/h/kg vs. 0.66 L/h/kg) ([@B30]) than humans.

###### 

Pharmacokinetic (PK) Parameter Summary for Zolpidem, ZPCA, and ZCA in each Group.

  Parameter                               HL     Tmax    Cmax     SE_Cmax   AUCall   SE_AUCall
  --------------------------------------- ------ ------- -------- --------- -------- -----------
  **Zolpidem**                                                                       
  Males                                   3.26   1       68.1     15.61     231.82   25.15
  Males+disulfiram                        2.89   0.083   127.5    9.5       141.69   12.94
  Females+disulfiram                      2.76   0.083   145      34        302.8    23.97
  Females                                 8.39   1       112.35   17.65     537.77   50.36
  Castrated Males                         5.96   0.25    109.07   20.44     339.72   52.6
  **Zolpidem Phenyl 4-Carboxylic Acid**                                              
  Males                                   3.17   1       101.7    44.18     257.38   37.28
  Males+disulfiram                        3.54   0.083   123      5         278.2    20.94
  Females+disulfiram                      2.62   0.25    162.63   40.22     324.83   25.87
  Females                                 4.22   0.5     88.25    32.75     352.1    47.29
  Castrated males                         6.16   1       105.77   45.07     316.84   55.49
  **Zolpidem 6-Carboxylic Acid**                                                     
  Males                                   6.43   1       2.13     0.97      9.17     1.12
  Males+disulfiram                        9.2    0.083   2.52     0.455     8.69     0.062
  Females+disulfiram                      4.12   1       3.64     0.66      13.48    0.84
  Females                                 6.38   3       1.74     0.164     10.31    0.591
  Castrated males                         6.27   2       1.65     0.176     6.92     0.432

Zolpidem phenyl 4-carboxylic acid was the predominant metabolite formed through the Cyp3a → Adh → Aldh pathway, with a metabolic ratio (metabolite:parent) for *C*~MAX~ (1.39) and AUC (1.25) that was 47-fold and 27-fold greater than that of ZCA (0.029 and 0.045, respectively). This is consistent with an *in vitro* study that demonstrated ZPCA and ZCA account for 72--86% and 10%, respectively, of urinary metabolites ([@B18]; [@B32]).

Numerous studies demonstrate that zolpidem PD effects are related to plasma concentrations ([@B39]; [@B38]), that females have higher plasma concentrations than males ([@B20]), and metabolism by CYP3A does not explain this effect since females have similar or higher CYP3A activity than males ([@B42]). The present data suggest that sex differences in zolpidem PK are partly a function of increased absorption, which is most likely caused by previously observed sexual differences in Adh/Aldh expression in the GI tract ([@B12]; [@B1]; [@B41]). These enzymes are known to be even more sexually dimorphic in humans than in rats (fourfold vs. twofold) ([@B1]) ([@B31]), but this is the first study to address how Adh/Aldh variability affects zolpidem PK between sexes. It was previously demonstrated that female rats have greater activity of hepatic Adh than male rats (21.5 vs. 12.0 nmol/NADH/min/mg protein), suggesting testosterone reduces hepatic Adh expression, and therefore activity ([@B1]). This was confirmed when castrated male rats showed similar hepatic Adh specific activity to female rats (17.5 vs. 21.5 nmol/NADH/min/mg protein). The opposite was true for gastric Adh, where female and castrated male rats had lower gastric Adh specific activity (11.0 and 12.9 nmol/NADH/min/mg protein, respectively) vs. uncastrated male rats (20.5 nmol/NADH/min/mg protein) for ethanol ([@B1]). Therefore, female and castrated male rats with lower testosterone levels exhibited greater hepatic, but lower gastric, Adh activity, which manifested as less gastric metabolism (i.e., faster absorption rate, earlier *T*~MAX~, higher *C*~MAX~) and greater hepatic Adh/Aldh metabolism (i.e., more metabolite exposure). Consistent with these findings, our data showed female rats have an approximate 1.7-fold higher *C*~MAX~ and castrated males having an approximate 1.5-fold higher *C*~MAX~, and earlier *T*~MAX~ than uncastrated males. This suggests that gonadal testosterone secretion promotes gastric drug metabolism thereby acting as a barrier to drug bioavailability.

Further confirming that Adh/Aldh is responsible for sex differences in zolpidem absorption, disulfiram also caused both increased absorption rate (earlier *T*~MAX~, higher *C*~MAX~) and counterintuitively a more rapid elimination rate, which is manifested as a lower AUC in disulfiram-treated rats regardless of sex. Thus, zolpidem appears to be metabolized in part by gastric Adh/Aldh that reduces drug absorption into the systemic circulation. Similar to observations with ethanol ([@B7]), a reduction in metabolism through this pathway would be expected to cause both a greater rate of absorption and increased bioavailability ([@B8]; [@B19], [@B20]). Although the specifics of *in vivo* Adh/Aldh metabolism have not been elucidated, we suggest that this is the most plausible explanation for the higher *C*~MAX~, earlier *T*~MAX~, and yet lower AUC in disulfiram-treated rats.

While previous clinical studies have reported lower systemic clearance (calculated as Dose/AUC) in females vs. males (2.7--2.8 vs. 3.9--4.0 ml/min/kg, *p* \< 0.06), consistent with females having greater overall exposure, the mechanisms behind the increased exposure are not fully understood ([@B22], [@B20]). It is plausible that a major source of the increased exposure in females is due to their greater absorption due to lower gastric Adh/Adh, as was observed for ethanol ([@B15]). A lower "clearance" in females is not necessarily a factor of impaired metabolism/elimination, but rather due to increased exposure, likely from increased absorption/oral bioavailability from lower gastric ADH expression. Although the sublingual route demonstrated comparable fold-change increases in exposure (1.4-fold) in females vs. males compared to the enteral route (immediate release), this observed sex difference in exposure, and therefore clearance, in sublingual route is possibly due to ADH expression in the oral and gastric mucosa ([@B28]; [@B24]). Thus, the sublingual route could still be affected by gender differences in ADH expression.

Future studies should compare zolpidem PK following IV and oral administration to study the specific contribution of gastric and liver metabolism to overall zolpidem disposition and should clarify which specific Adh/Aldh isozymes are responsible for zolpidem metabolism. Such studies should also investigate whether first-pass metabolism is also related to sex differences in the pharmacological effects and side effects if zolpidem. Additionally, zolpidem (more likely the CYP-mediated hydroxyl metabolites) has been demonstrated to be a weak (*K*i = 122 uM) mechanism-based inhibitor (both time- and concentration-dependent) for CYP3A4, but due to the relatively high *K*i value, was deemed to be unlikely to cause clinical drug interactions ([@B33]). Previous studies have only focused on pharmacodynamics interactions in the brain and not differences in ADH expression affecting bioavailability ([@B9]; [@B10]; [@B37]).
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